sign in sign up
<<
Home , AllTrials, Andrew Witty, Beecham Group, Block Drug, Chris Gent, Emma Walmsley

GlaxoSmithKline - Wikipedia https://en.wikipedia.org/wiki/GlaxoSmithKline

GlaxoSmithKline From Wikipedia, the free encyclopedia

GlaxoSmithKline plc (GSK) is a British pharmaceutical company headquartered in Brentford, . Established in 2000 by a merger of Glaxo Wellcome and GlaxoSmithKline SmithKline Beecham, GSK was the world's sixth largest pharmaceutical company as of 2015, after Pfizer, , Merck, Hoffmann-La Roche and Sanofi.[n 1][3] became CEO on 31 March 2017 and is the first female CEO of the company.

The company has a primary listing on the and is a constituent of the FTSE 100 Index. As of August 2016 it had a market capitalisation of £81 billion (around $107 billion), the fourth largest on the London Stock Exchange.[4] It has a secondary listing on the Stock Exchange.

GSK's drugs and earned £21.3 billion in 2013.[5] Its top-selling products that year were Advair, Avodart, Flovent, Augmentin, Lovaza and Lamictal. GSK's consumer products, which earned £5.2 billion in 2013, include and Aquafresh , the malted-milk drink , Abreva for cold sores, Breathe Right nasal strips, Nicoderm and nicotine replacements, and Night Nurse, a cold remedy.[6] The company developed the first , RTS,S, which it said in 2014 it would make available for five percent above cost.[7] Legacy products developed at GSK include several listed in the World Health Model List of Essential Medicines, such as , , and .

In 2012, GSK pleaded guilty to promotion of drugs for unapproved uses, failure to GSK's head office, Brentford, London TW8 report safety data, and kickbacks to physicians in the United States and agreed to pay a Type Public limited company $3 billion (£1.9bn) settlement, the largest settlement in the country by a drug LSE: GSK company.[8] Traded as (http://www.londonstockexchange.com /exchange/searchengine /search.html?q=GSK) Contents NYSE: GSK (https://www.nyse.com /quote/XNYS:GSK) 1 History FTSE 100 Component 1.1 Glaxo Wellcome Industry Pharmaceutical 1.2 SmithKline Beecham 1.3 GlaxoSmithKline Consumer goods 1.4 Venture arms Predecessor Glaxo plc 2 Research, products Wellcome plc 2.1 Pharmaceuticals plc 2.2 Kline & French 2.3 Consumer healthcare Beckman Companies 2.4 Facilities Smith plc 2.5 Scientific recognition 3 Operations and acquisitions since 2001 Founded December 2000 3.1 2001–2010 Headquarters Brentford, London, England, U.K. 3.2 2011–present Area served Worldwide 4 Philanthropy and social responsibility 5 2012 criminal and civil settlement Key people Sir 5.1 Overview (Chairman) 5.2 (Avandia) Emma Walmsley 5.3 (Paxil/Seroxat) (CEO) 5.4 (Wellbutrin) Products Pharmaceuticals, vaccines, oral 6 Other controversies healthcare, nutritional products, over- 6.1 Antitrust case over the-counter medicines 6.2 Revenue £27.889 billion (2016)[1] 6.3 SB Pharmco Operating [1] 6.4 China £2.598 billion (2016) income 6.5 Market manipulation in the UK [1] 6.6 Miscellaneous Net income £1.062 billion (2016) 7 Diagram of acquisition history Number of 99,300 (2016)[2] 8 See also employees 9 Notes Subsidiaries 10 References www.gsk.com (http://www.gsk.com/) 11 External links Website

History

1 di 14 02/07/17, 14:32 GlaxoSmithKline - Wikipedia https://en.wikipedia.org/wiki/GlaxoSmithKline

Glaxo Wellcome

Glaxo was founded in the 1850s as a general trading company in Bunnythorpe, , by a Londoner, Joseph Edward Nathan.[9] In 1904 it began producing dried-milk baby food, first known as Defiance, then as Glaxo (from lacto), under the slogan "Glaxo builds bonny babies."[10][11]:306[12] The Glaxo Laboratories sign is still visible (right) on what is now a car repair shop on the main street of Bunnythorpe. The company's first pharmaceutical product, produced in 1920, was vitamin D.[11]:306

Glaxo Laboratories opened new units in London in 1935. The company bought two companies, Joseph Nathan and Allen & Hanburys in 1947 and 1958 respectively. The Scottish pharmacologist David Jack was working for Allen & Hanbury's when Glaxo took it over; he went on to lead the company's R&D until 1987.[11]:306 After the company bought Meyer Laboratories in 1978, it began to play an important role in the US market. In 1983 the American arm, Glaxo Inc., moved to Park (US The historic Glaxo factory in Bunnythorpe, New [12] headquarters/research) and Zebulon (US manufacturing) in . Zealand, with the Glaxo Laboratories sign still visible Burroughs Wellcome & Company was founded in 1880 in London by the American pharmacists and Silas Burroughs. The Wellcome Tropical Research Laboratories opened in 1902. In the 1920s Burroughs Wellcome established research and manufacturing facilities in Tuckahoe, New York,[13]:18[14][15] which served as the US headquarters until the company moved to Research Triangle Park in North Carolina in 1971.[16] The Nobel Prize winning scientists Gertrude B. Elion and George H. Hitchings worked there and invented drugs still used many years later, such as mercaptopurine.[17] In 1959 the Wellcome Company bought Cooper, McDougall & Robertson Inc to become more active in animal health.[12] Glaxo and Burroughs Wellcome merged in 1995 to form Glaxo Wellcome.[18][11]:309 Glaxo restructured its R&D operation that year, cutting 10,000 jobs worldwide, closing its R&D facility in Beckenham, Kent, and opening a Medicines Research Centre in Stevenage, .[19][20][21] Also that year, Glaxo Wellcome acquired the California-based Affymax, a leader in the field of .[22]

By 1999 Glaxo Wellcome had become the world's third-largest pharmaceutical company by revenues (behind Novartis and Merck), with a global market share of around 4 per cent.[23] Its products included Imigran (for the treatment of ), (Ventolin) (for the treatment of asthma), Zovirax (for the treatment of coldsores), and Retrovir and Epivir (for the treatment of AIDS). In 1999 the company was the world's largest manufacturer of drugs for the treatment of asthma and HIV/AIDS.[24] It employed 59,000 people, including 13,400 in the UK, had 76 operating companies and 50 manufacturing facilities worldwide, and seven of its products were among the world's top 50 best- selling pharmaceuticals. The company had R&D facilities in Hertfordshire, Kent and London, and manufacturing plants in Scotland and the north of England. It had R&D centres in the US and Japan, and production facilities in the US, Europe and the Far East.[25]

SmithKline Beecham

In 1843 launched his Beecham's Pills laxative in England, giving birth to the Beecham Group. In 1859 Beecham opened its first factory in St Helens, . By the 1960s Beecham was extensively involved in pharmaceuticals.[12]

John K. Smith opened his first pharmacy in in 1830. In 1865 joined the business, which 10 years later became Smith, Kline & Co. In 1891 it merged with French, Richard and Company, and in 1929 changed its name to Smith Kline & French Laboratories as it focused more on research. Years later it bought Norden Laboratories, a business doing research into animal health, and Recherche et Industrie Thérapeutiques in Belgium in 1963 to focus on vaccines. The company began to expand globally, buying seven laboratories in Canada and the United States in 1969. In 1982 it bought , a manufacturer of eye and skincare products.[12]

SmithKline & French merged with Beckman Inc. in 1982 and changed its name to SmithKline Beckman. In 1988 it bought its biggest competitor, International Clinical Laboratories, and in 1989 merged with Beecham to form SmithKline Beecham Plc. The headquarters moved from the United States to England. To expand R&D in the United States, the company bought a new research center in 1995; another opened in 1997 in England at New Frontiers Science Park, Harlow.[12] Beecham's Clock Tower, constructed 1877, part of the Beecham's factory, St Helens GlaxoSmithKline

Glaxo Wellcome and SmithKline Beecham announced their intention to merge in January 2000. The merger was completed in December that year, forming GlaxoSmithKline (GSK).[26][27] The company's global headquarters are at GSK House, Brentford, London, officially opened in 2002 by then-Prime Minister . The building was erected at a cost of £300 million and as of 2002 was home to 3,000 administrative staff.[28]

Venture arms

SR One was established in 1985 by SmithKline Beecham to invest in new biotechnology companies and continued operating after GSK was formed; by 2003 GSK had formed another subsidiary, GSK Ventures, to out-license or start new companies around drug candidates that it did

2 di 14 02/07/17, 14:32 GlaxoSmithKline - Wikipedia https://en.wikipedia.org/wiki/GlaxoSmithKline

not intend to develop further.[29] As of 2003, SR One tended to invest only if the company aligned with GSK's business.[29]

SR One was led by:

1985 to 1999: Peter Sears[30] 1999 to 2001: Brenda Gavin[31] 2001 to 2003: Barbara Dalton[31] 2004 to ? Maxine Gowen[32] ? to ?: Joyce Lonergan[33] ? to ?: Tamar Howson[33] 2008 to 2010: Russell Greig[34] 2010 to 2011: Christoph Westphal[35][33] 2011: Jens Eckstein[36] Research, products

Pharmaceuticals

GSK manufactures products for major disease areas such as asthma, cancer, infections, diabetes and mental health. Its biggest-selling in 2013 were Advair, Avodart, Flovent, Augmentin, Lovaza, and Lamictal; its drugs and vaccines earned £21.3 billion that year. Other top-selling products include its asthma/COPD inhalers Advair, Ventolin, and Flovent; its diphtheria/tetanus/ Infanrix and its B vaccine; the epilepsy drug Lamictal, and the antibacterial Augmentin.[5]:220

Medicines historically discovered or developed at GSK and its legacy companies and now sold as generics include amoxicillin[37] and amoxicillin-clavulanate,[38] -clavulanate,[39] ,[40] and [41] for bacterial infections, zidovudine for HIV infection, valacyclovir for herpes infections, for parasitic infections, for migraine, for epilepsy, bupropion and paroxetine for major depressive disorder, and for gastroesophageal reflux disorder, mercaptopurine[42] and thioguanine[43] for the treatment of leukemia, for ,[44] pyrimethamine for malaria,[45] and the antibacterial .[43]

Among these, albendazole, amoxicillin, amoxicillin-clavulanate, allopurinol, mercaptopurine, mupriocin, pyrimethamine, ranitidine, thioguanine, trimethoprim and zidovudine are listed on the World Health Organization's list of essential .[46]

Malaria vaccine

In 2014 GSK applied for regulatory approval for the first malaria vaccine.[47] Malaria is responsible for over 650,000 deaths annually, mainly in Africa.[48] Known as RTS,S, the vaccine was developed as a joint project with the PATH vaccines initiative and the Bill and Melinda Gates Foundation. The company has committed to making the vaccine available in developing countries for five percent above the cost of production.[7]

As of 2013 RTS,S, which uses GSK's proprietary AS01 adjuvant, was being examined in a Phase 3 trial in eight African countries. PATH reported that "[i]n the 12-month period following vaccination, RTS,S conferred approximately 50% protection from clinical Plasmodium falciparum disease in children aged 5-17 months, and approximately 30% protection in children aged 6-12 weeks when administered in conjunction with Expanded Program for Immunization (EPI) vaccines."[49] In 2014 Glaxo said it had spent more than $350 million and expected to spend an additional $260 million before seeking regulatory approval.[50][51] A second generation malaria vaccine is being evaluated in Phase 2 clinical trials.[52]

Consumer healthcare

GSK's consumer healthcare division, which earned £5.2 billion in 2013, sells oral healthcare, including Aquafresh, Maclean's and Sensodyne ; and drinks such as Horlicks, Boost, a chocolate-flavoured malt drink sold in , and formerly and Ribena, sold in 2013 to for £1.35bn.[53] Other products include Abreva to treat cold sores; Night Nurse, a cold remedy; Breathe Right nasal strips; and Nicoderm and Nicorette nicotine replacements.[54] In March 2014 it recalled Alli, an over-the-counter weight-loss drug, in the United States and Puerto Rico because of possible tampering, following customer complaints.[55]

Facilities

As of 2013 GSK had offices in over 115 countries and employed over 99,000 people, 12,500 in R&D. The company's single largest market is the United States. Its US headquarters are in The Navy Yard, Philadelphia, and Research Triangle Park, North Carolina; its consumer- products division is in Moon Township, Pennsylvania.[5]:7[56] Company facilities include:

R&D sites: England (Stevenage, Stockley Park, Ware), the US (Research Triangle Park, North Carolina, and Collegeville, Pennsylvania), Canada, China, Croatia, France and India. GSK is also planning to open a R&D centre in partnership with McLaren Technology Group at the McLaren Technology Campus. Centres for biopharmaceutical products: the US (Marietta, Pennsylvania, and Hamilton, Montana), Belgium, Canada, Germany and Hungary. Manufacturing sites for prescription products: (Scotland (Irvine and Montrose), England (Ware, Barnard Castle, and

3 di 14 02/07/17, 14:32 GlaxoSmithKline - Wikipedia https://en.wikipedia.org/wiki/GlaxoSmithKline

Ulverston), Ireland (Cork), the US (Bristol, Tennessee; King of Prussia, Pennsylvania; Zebulon, North Carolina), as well as , Belgium, France, Italy, , , Puerto Rico, Romania and Singapore. Manufacturing sites for consumer products: England (Maidenhead), Ireland (Dungarvan), the US (Aiken, South Carolina; Oak Hill, New York; St. Louis, Missouri), Brazil, Canada and .

Scientific recognition

Four GlaxoSmithKline scientists have been recognized by the Nobel Committee for their contributions to basic medical science and/or therapeutics development.

Henry Dale, a former student of , received the 1936 Nobel Prize in Medicine for his work on the chemical transmission of neural impulses. Dale served as a pharmacologist and then as Director of the Wellcome Physiological Research Laboratories from 1904 to 1914, and later served as Trustee and Chairman of the Board of the .[57] of Wellcome Research Laboratories shared the 1982 Nobel Prize for Medicine for his work on prostaglandin biology and the discovery of . Vane served as Group Director for The Wellcome Foundation from 1973 to 1985.[58] Gertrude B. Elion and George Hitchings, both of the Wellcome Research Laboratories, shared the 1988 Nobel Prize in Medicine with Sir James W. Black ""for their discoveries of important principles for drug treatment"." Elliot and Hitchings were responsible for the discovery of a plethora of important drugs, including mercaptopurine[42] and thioguanine[43] for the treatment of leukemia, the immunosuppressant azothioprine,[59] allopurinol for gout,[44] pyrimethamine for malaria,[45] the antibacterial trimethoprim,[43] acyclovir for herpes virus infection,[60] and nelarabine for cancer treatment.[61] Operations and acquisitions since 2001

2001–2010

GSK completed the acquisition of New Jersey-based in 2001 for US$1.24 billion.[62] In 2006 GSK acquired the US-based consumer healthcare company CNS Inc., whose products included Breathe Right nasal strips and FiberChoice dietary supplements, for US$566 million in cash.[63]

Chris Gent, previously CEO of , was appointed chairman of the board in 2005.[64]

GSK opened its first R&D centre in China in 2007, in , initially focused on neurodegenerative diseases.[65]

[66] []] became the chief executive officer in 2008. Witty joined Glaxo in Andrew Witty, GSK's CEO since May 2008 1985 and had been president of GSK's Pharmaceuticals Europe since 2003.[67]

In 2009 GSK acquired Stiefel Laboratories, then the world's largest independent dermatology drug company, for US$3.6bn.[68] In November the FDA approved GSK's vaccine for 2009 H1N1 influenza protection, manufactured by the company's ID Biomedical Corp in Canada.[69] Also in November 2009 GSK formed a joint venture with Pfizer to create ViiV Healthcare, which specializes in HIV research.[70] In 2010 the company acquired Laboratorios Phoenix, an Argentine pharmaceutical company, for US$253m,[71] and the UK-based sports nutrition company Maxinutrition for £162 million (US$256 million).[72]

2011–present

In 2011, in a $660-million deal, Prestige Brands Holdings took over 17 GSK brands with sales of $210 million, including BC Powder, Beano, Ecotrin, Fiber Choice, Goody's Powder, Sominex and Tagamet.[73] In 2012 the company announced that it would invest £500 million in manufacturing facilities in Ulverston, northern England, designating it as the site for a previously announced biotech plant.[74] In May that year it acquired CellZome, a German biotech company, for US$98 million,[75] and in June worldwide rights to (Toctino), an eczema drug, for $302 million.[76] In 2013 GSK acquired (HGS) for $3 billion; the companies had collaborated on developing the drug (Benlysta), for , and darapladib for .[77]

In March 2014 GSK paid $1 billion to raise its stake in its Indian pharmaceutical unit, GlaxoSmithKline Pharmaceuticals, to 75 percent as part of a move to focus on emerging markets.[78] In April 2014 Novartis and Glaxo agreed on more than $20 billion in deals, with Novartis selling its vaccine business to GSK and buying GSK's cancer business.[79][80] In February 2015 GSK announced that it would acquire GlycoVaxyn, a Swiss pharmaceutical company, for $190 million,[81] and in June that year that it would sell two drugs to Pfizer, Nimenrix and Mencevax for around $130 million.[82]

Philip Hampton, at that time chair of the , became GSK chairman in September 2015.[83]

In September 2016 the company announced that Witty would be succeeded as CEO by Emma Walmsley in March 2017; Walmsley was a management professional originally from Lancashire with a background in marketing.[84] Philanthropy and social responsibility

4 di 14 02/07/17, 14:32 GlaxoSmithKline - Wikipedia https://en.wikipedia.org/wiki/GlaxoSmithKline

Since 2010 GlaxoSmithKline has several times ranked first among pharmaceutical companies on the Global Access to Medicines Index, which is funded by the Bill and Melinda Gates Foundation.[85] In 2014 the , an LGBT-rights advocacy group gave GSK a score of 100 percent in its Corporate Equality Index.[86]

GSK has been active, with the World Health Organization (WHO), in the Global Alliance to Eliminate (GAELF). Around 120 million people globally are believed to be infected with lymphatic filariasis.[87] In 2012 the company endorsed the London Declaration on Neglected Tropical Diseases; it agreed to donate 400 million albendazole tablets to the WHO each year to fight soil-transmitted helminthiasis and to provide 600 million albendazole tablets every year for lymphatic filariasis until the disease is eradicated.[88] As of 2014 over 5 billion treatments had been delivered, and 18 of 73 countries in which the disease is considered endemic had progressed to the GlaxoSmithKline, Center City, Philadelphia surveillance stage.[89]

In 2009 the company said it would cut drug prices by 25 percent in 50 of the poorest nations, release intellectual property rights for substances and processes relevant to neglected disease into a patent pool to encourage new drug development, and invest 20 percent of profits from the least-developed countries in medical infrastructure for those countries.[90][91] Médecins Sans Frontières welcomed the decision, but criticized GSK for failing to include HIV patents in its patent pool and for not including middle-income countries in the initiative.[92]

In 2013 GSK licensed its HIV portfolio to the Medicines Patent Pool for use in children, and agreed to negotiate a license for , an then in clinical development.[93] In 2014 this license was extended to include dolutegravir and adults with HIV. The licenses include countries in which 93 percent of adults and 99 percent of children with HIV live.[94] Also in 2013 GSK joined AllTrials, a British campaign to ensure that all clinical trials are registered and the results reported. The company said it would make its past clinical-trial reports available and future ones within a year of the studies' end.[95] 2012 criminal and civil settlement

Overview

In July 2012 GSK pleaded guilty in the United States to criminal charges, and agreed to pay $3 billion, in what was the largest settlement until then between the Justice Department and a drug company. The $3 billion included a criminal fine of $956,814,400 and forfeiture of $43,185,600. The remaining $2 billion covered a civil settlement with the government under the . The investigation was launched largely on the basis of information from four whistleblowers who filed (whistleblower) lawsuits against the company under the False Claims Act.[8]

The charges stemmed from GSK's promotion of the anti-depressants Paxil (paroxetine) and Wellbutrin (bupropion) for unapproved uses from 1998–2003, specifically as suitable for patients under the age of 18, and from its failure to report safety data about Avandia (rosiglitazone), both in violation of the Federal Food, Drug, and Cosmetic Act. Other drugs promoted for unapproved uses were two inhalers, Advair (fluticasone/) and Flovent (fluticasone propionate), as well as Zofran (), Imitrex (sumatriptan), Lotronex () and Valtrex ().[8]

The settlement also covered reporting false best prices and underpaying rebates owed under the Medicaid Drug Rebate Program, and kickbacks to physicians to prescribe GSK's drugs. There were all-expenses-paid spa treatments and hunting trips for doctors and their spouses, speakers' fees at conferences, and payment for articles ghostwritten by the company and placed by physicians in medical journals.[8] The company set up a ghostwriting programme called CASPPER, initially to produce articles about Paxil but which was extended to cover Avandia.[96]

As part of the settlement GSK signed a five-year Corporate Integrity Agreement with the Department of Health and Human Services, which obliged the company to make major changes in the way it did business, including changing its compensation programmes for its sales force and executives, and to implement and maintain transparency in its research practices and publication policies.[8] It announced in 2013 that it would no longer pay doctors to promote its drugs or attend medical conferences, and that its sales staff would no longer have prescription targets.[97]

Rosiglitazone (Avandia)

The 2012 settlement included a criminal fine of $242,612,800 for failing to report safety data to the FDA about Avandia (rosiglitazone), a diabetes drug approved in 1999, and a civil settlement of $657 million for making false claims about it. The Justice Department said GSK had promoted rosiglitazone to physicians with misleading information, including that it conferred cardiovascular benefits despite an FDA-mandated label warning of cardiovascular risks.[8]

In 1999 John Buse, a diabetes specialist, told medical conferences that rosiglitazone might carry an increased risk of cardiovascular problems. GSK threatened to sue him, called his university head of department, and persuaded him to sign a retraction.[98] GSK raised questions internally about the drug's safety in 2000, and in 2002 the company ghostwrote an article in Circulation describing a GSK- Rosiglitazone funded that suggested rosiglitazone might have a beneficial effect on cardiovascular risk.[99] From 2001 reports began to link the (the class of drugs to which rosiglitazone belongs) to .[100] In April that year GSK began a six-year, open-label, randomized trial, known as RECORD, to

5 di 14 02/07/17, 14:32 GlaxoSmithKline - Wikipedia https://en.wikipedia.org/wiki/GlaxoSmithKline

examine rosiglitazone and cardiovascular events.[101] Two GSK meta-analyses in 2005 and 2006 showed an increased risk of cardiovascular problems with rosiglitazone; the information was passed to the FDA and posted on the company website, but not otherwise published. By December 2006 rosiglitazone had become the top-selling diabetes drug, with annual sales of US$3.3 billion.[100]

In June 2007 the New England Journal of Medicine published a meta-analysis that associated the drug with an increased risk of heart attack.[102] GSK had reportedly tried to persuade one of the authors, Steven Nissen, not to publish it, after receiving an advance copy from one of the journal's peer reviewers, a GSK consultant.[103] In July 2007 FDA scientists suggested that rosiglitazone had caused 83,000 excess heart attacks between 1999 and 2007.[104]:4[105] The FDA placed restrictions on the drug, including adding a , but did not withdraw it.[106] (In 2013 the FDA rejected that the drug had caused excess heart attacks.)[107] A Senate Finance Committee inquiry concluded in 2010 that GSK had sought to intimidate scientists who had concerns about rosiglitazone.[104] In February that year the company tried to halt publication of an editorial about the controversy by Nissen in the European Heart Journal.[108]

The results of GSK's RECORD trial were published in June 2009. It confirmed an association between rosiglitazone and an increased risk of heart failure and fractures, but not of heart attack, and concluded that it "does not increase the risk of overall cardiovascular morbidity or mortality compared with standard glucose-lowering drugs."[101] Steven Nissan and Kathy Wolkski argued that the study's low event rates reduced its statistical power.[109] In September 2009 rosiglitazone was suspended in Europe.[110] The results of the RECORD study were confirmed in 2013 by the Duke Institute, in an independent review required by the FDA.[111] In November that year the FDA lifted the restrictions it had placed on the drug.[112] The boxed warning about heart attack was removed; the warning about heart failure remained in place.[107]

Paroxetine (Paxil/Seroxat)

GSK was fined for promoting Paxil/Seroxat (paroxetine) for treating depression in the under-18s, although the drug had not been approved for pediatric use.[8] Paxil had $4.97 billion worldwide sales in 2003.[113] The company conducted nine clinical trials between 1994 and 2002, none of which showed that Paxil helped children with depression.[114] From 1998 to 2003 it promoted the drug for the under-18s, paying physicians to go on all-expenses paid trips, five-star hotels and spas.[8] From 2004 Paxil's label, along with those of similar drugs, included an FDA-mandated boxed warning that it might increase the risk of and behaviour in patients under 18.[8]

An internal SmithKline Beecham document said in 1998, about withheld data from two GSK studies: "It would be commercially unacceptable to include a statement that [pediatric] efficacy had not been Paroxetine, known as Paxil and demonstrated, as this would undermine the profile of paroxetine."[113][115] The company ghostwrote Seroxat an article, published in 2001 in the Journal of the American Academy of Child and Adolescent Psychiatry, that misreported the results of one of its clinical trials, .[8][116] The article concluded that Paxil was "generally well tolerated and effective for major depression in adolescents."[117] The suppression of the research findings is the subject of (2008) by Alison Bass.[118]

For 10 years GSK marketed Paxil as non-habit forming. In 2001 35 patients filed a class-action suit alleging they had suffered withdrawal symptoms, and in 2002, a Los Angeles court issued an injunction preventing GSK from advertising that the drug was not habit forming.[119] The court withdrew the injunction after the FDA objected that the court had no jurisdiction over drug marketing that the FDA had approved.[120] In 2003, a World Health Organization committee reported that Paxil was among the top 30 drugs, and top three , for which dependence had been reported.[121][n 2]

Bupropion (Wellbutrin)

The company was also fined for promoting Wellbutrin (bupropion) – approved at the time for major depressive disorder and also sold as a smoking-cessation aid, Zyban – for weight loss and the treatment of attention deficit hyperactivity disorder, sexual dysfunction and substance addiction. GSK paid doctors to promote these off-label uses, and set up supposedly independent advisory boards and Continuing Medical Education programmes.[8] Other controversies

Antitrust case over griseofulvin

In the 1960s Glaxo Group Ltd. (Glaxo) and Imperial Chemical Industries (ICI) each owned patents covering various aspects of the antifungal drug griseofulvin.[122]:54, nn. 1–2[123] They created a patent pool by cross-licensing their patents, subject to express licensing restrictions that the chemical from which the "finished" form of the drug (tablets and capsules) was made must not be resold in bulk form, and they licensed other drug companies to sell the drug in finished form and subject to similar restrictions.[122]:54–55[123] The effect and intent of the bulk-sale restriction was to keep the drug chemical out of the hands of small companies that might act as price-cutters, and the effect was to maintain stable, uniform prices.[124][125][126]

The United States brought an antitrust suit against the two companies—United States v. Glaxo Group Ltd.—charging them with violation of the Sherman Act and also seeking to have the patents declared invalid.[122]:55[123] The trial court found that the defendants had engaged in several unlawful conspiracies, but dismissed the part of the suit seeking invalidation of patents and refused to grant as relief mandatory sales of the bulk drug chemical and compulsory licensing of the patents.[122]:56[123] The government appealed to the Supreme Court, which reversed, in United States v. Glaxo Group Ltd., 410 U.S. 52 (1973).[123]

6 di 14 02/07/17, 14:32 GlaxoSmithKline - Wikipedia https://en.wikipedia.org/wiki/GlaxoSmithKline

Ribena

There were concerns in the 2000s about the sugar and vitamin content of Ribena, a blackcurrant-based syrup and owned by GSK until 2013. Produced in England by H.W. Carter & Co from the 1930s, the company's unbranded syrup was distributed to children as a source of during World War II, which gave the drink a as good for health. Beecham bought H. W. Carter in 1955.[127]

In 2001 the British Advertising Standards Authority (ASA) required GSK to withdraw its claim that Ribena Toothkind, a lower-sugar variety, did not encourage tooth decay. A company poster showed bottles of Toothkind in place of the bristles on a toothbrush. The ASA's ruling was upheld by the High Court.[128] In 2007 GSK was fined $217,000 in New Zealand over its claim that ready-to-drink Ribena contained high levels of vitamin C, after it was found to contain no detectable vitamin C.[129] In 2013 GSK sold Ribena and another drink, Lucozade, to the Japanese multinational Suntory for £1.35 billion.[53]

SB Pharmco Puerto Rico

In 2010 the US Department of Justice announced that GSK would pay a $150 million criminal fine and forfeiture, and a civil settlement of $600 million under the False Claims Act. The fines stemmed from production of improperly made and adulterated drugs from 2001 to 2005 at GSK's subsidiary, Old Ribena bottle, year unknown, SB Pharmco Puerto Rico Inc., in Cidra, Puerto Rico, which at the time produced $5.5 billion of made by Beecham Products, products each year. The drugs involved were Kytril, an antiemetic; Bactroban, used to treat skin Brentford, Middlesex; the label states: infections; Paxil, the anti-depressant; and Avandamet, a diabetes drug.[130] GSK closed the factory in "widely used in hospitals and clinics." 2009.[131]

According to , the case began in 2002 when GSK sent experts to fix problems cited by the FDA. The lead inspector recommended recalls of defective products, but they were not authorized; she was fired in 2003 and filed a whistleblower lawsuit. In 2005 federal marshals seized $2 billion worth of products, the largest such seizure in history. In the 2010 settlement SB Pharmco plead guilty to criminal charges, and agreed to pay $150 million in a criminal fine and forfeiture, at that time the largest such payment ever by a manufacturer of adulterated drugs, and $600 million in civil penalties to settle the civil lawsuit.[131]

China

In 2013 Chinese authorities announced that, since 2007, GSK had funnelled HK$3.8 billion in kickbacks to GSK managers, doctors, hospitals and others who prescribed their drugs, using over 700 travel agencies and consulting firms.[132] Chinese authorities arrested four GSK executives as part of a four-month investigation into claims that doctors were bribed with cash and sexual favours.[133] In 2014 a Chinese court found the company guilty of bribery and imposed a fine of $490 million. Mark Reilly, the British head of GSK's Chinese operations, received a three-year suspended prison sentence after a one-day trial held in secret.[134] Reilly was reportedly deported from China and dismissed by the company.[135]

Market manipulation in the UK

In February 2016 the company was fined more than £37 million by the Competition and Markets Authority for paying Generics UK, Alpharma and Norton Healthcare more than £50m between 2001 and 2004, in order to keep generic varieties of Paroxetine out of the NHS market. The generics companies were fined a further £8 million. At the end of 2003 when generics were available in the UK the price of Paroxetine dropped 70%.[136]

Miscellaneous

Italian police sought bribery charges in May 2004 against 4,400 doctors and 273 GSK employees. GSK and its predecessor were accused of having spent £152m on physicians, pharmacists and others, giving them cameras, computers, holidays and cash. Doctors were alleged to have received cash based on the number of patients they treated with a cancer drug, (Hycamtin).[137] The following month prosecutors in Munich accused 70–100 doctors of having accepted bribes from SmithKline Beecham between 1997 and 1999. The inquiry was opened over allegations that the company had given over 4,000 hospital doctors money and free trips.[138] All charges were dismissed by the Verona court in January 2009.[139]

In 2006 in the United States GSK settled the largest tax dispute in IRS history, agreeing to pay $3.1 billion. At issue were Zantac and other products sold in 1989–2005. The case revolved around intracompany transfer pricing—determining the share of profit attributable to the US subsidiaries of GSK and subject to tax by the IRS.[140]

The UK's Serious Fraud Office (SFO) opened a criminal inquiry in 2014 into GSK's sales practices, using powers granted by the Bribery Act 2010.[141] The SFO said it was collaborating with Chinese authorities to investigate bringing charges in the UK related to GSK's activities in China, Europe and the Middle East.[142] Also as of 2014 the US Department of Justice was investigating GSK with reference to the Foreign Corrupt Practices Act.[143] Diagram of acquisition history

7 di 14 02/07/17, 14:32 GlaxoSmithKline - Wikipedia https://en.wikipedia.org/wiki/GlaxoSmithKline

The following is an illustration of the company's major and historical predecessors (this is not a comprehensive list):

French, Richards and Company (Acq 1891)

Smith, Kline and Company (Founded Smith, Kline & French 1830) (reorganized 1929 into Smith Kline and French Laboratories) Lever SmithKline-RIT Brothers (renamed 1968) (Angio-seal div. Acq 1900

Recherche et Industrie Thérapeutiques (Acq 1968)

Specialized Instruments Corp. (Acq 1954) Beckman Instruments, Inc. (Merged 1982, Sold 1989) Offner Electronics (Acq 1961)

SmithKline Beckman Allergan (renamed 1982) (Acq 1982, Sold 1989)

International Clinical Laboratories (Acq 1989)

Reckitt & Colman (Acq 1999) SmithKline Beecham plc (renamed 1989) Stiefel Laboratories (Acq 2000 by SmithKline Beckman)

Sanofi-Synthelabo (Acq 2001)

Norcliff Thayer (Acq 1986)

S. E. Massengill Company (Acq 1971)

Beecham Group Plc Beecham Group Ltd C.L. Bencard (merged 1989) (Acq 1953) Beecham Group Ltd (Renamed 1945) County Chemicals (Acq 1929)

GlaxoSmithKline Glaxo Wellcome Glaxo (Renamed 1995) (Merged 1995) Glaxo (Founded 1850)

Joseph Nathan (Acq 1947)

8 di 14 02/07/17, 14:32 GlaxoSmithKline - Wikipedia https://en.wikipedia.org/wiki/GlaxoSmithKline

Allen & Hanburys (Founded 1715, Acq 1958)

Margarine Unie (Angio-seal div, Acq 1924)

Meyer Laboratories (Acq 1978)

Affymax (Acq 1995)

McDougall & Robertson Inc (Acq 1959) Burroughs Wellcome (Merged 1995) Burroughs Wellcome & Company (Founded 1880)

Block Drug (Acq 2001)

CNS Inc. (Acq 2006)

Stiefel Laboratories (Acq 2009)

Laboratorios Phoenix (Acq 2010)

Maxinutrition (Acq 2010)

CellZome (Acq 2011)

Human Genome Sciences (Acq 2013)

Novartis (Vaccine div; Acq 2014)

GSK Cancer division (Sold 2014 to Novartis)

GlycoVaxyn (Acq 2015)

See also

List of toothpaste brands Index of oral health and dental articles Recherche et Industrie Thérapeutiques (R.I.T.) Galvani Bioelectronics Notes

1. Glaxo Wellcome was formed from Glaxo's 1995 acquisition of Burroughs Wellcome and SmithKline Beecham from the 1989 merger of the Beecham Group and the SmithKline Beckman Corporation. 2. World Health Organization Expert Committee on Drug Dependence, 2003: "The Committee noted the striking number of reports on paroxetine and 'withdrawal syndrome' ... The representative of Consumers International reported that a number of patients had experienced difficulty in withdrawing from SSRIs in general. It was agreed that withdrawal was indeed a problem in some patients, but there was a difference of opinion on the degree of dependence that was involved, given the possibility that the need for treatment of resistant or relapsing disease could make these drugs indispensable for patient care. The Committee expressed concern about the possibility of inappropriate prescribing resulting in the risk of problems of withdrawal

9 di 14 02/07/17, 14:32 GlaxoSmithKline - Wikipedia https://en.wikipedia.org/wiki/GlaxoSmithKline

outweighing the benefits of treatment with SSRIs."[121] References

/27/business/glaxo-to-acquire-affymax.html), The New York Times, 27 1. "Annual Report 2016" (http://annualreport.gsk.com/assets/downloads January 1995. /1_GSK.AR.FULL.V4.pdf) (PDF). Retrieved 7 April 2017. 23. "Outlook: Glaxo Wellcome" (http://www.independent.co.uk 2. "GlaxoSmithKline" (https://www.statista.com/statistics/266299 /news/business/outlook-glaxo-wellcome-1084036.html). The /number-of-employees-at--by-region/). Statista. Independent. 30 March 1999. Retrieved 7 April 2017. 24. "Company of the week: Glaxo Wellcome" 3. "The World's Biggest Public Companies" (http://www.forbes.com (http://www.independent.co.uk/news/business/company-of-the-week- /global2000/#industry:Pharmaceuticals), 2015 ranking, Forbes. glaxo-wellcome-1109929.html). The Independent. 1 August 1999. 4. "FTSE All-Share Index Ranking" (http://www.stockchallenge.co.uk 25. "Profile: Glaxo Wellcome" (http://news.bbc.co.uk/1/hi/business /ftse.php). stockchallenge.co.uk. /606752.stm). BBC News. 17 January 2000. 5. "Annual Report 2013" (http://www.gsk.com/content/dam/gsk/globals 26. "The new alchemy – The drug industry’s flurry of mergers is based on /documents/pdf/Annual-Report-2013.pdf) (PDF). GlaxoSmithKline. a big gamble" (http://www.economist.com/node/275655). The Retrieved 26 May 2014. Economist. 20 January 2000. 6. "Products" (http://www.gsk.com/products.html). GlaxoSmithKline 27. "Partners resolve their differences and unite at the second attempt" plc. Retrieved 16 November 2013. (http://www.nature.com/nature/journal/v405/n6783 7. Hester Plumridge (24 July 2014). "Glaxo Files Its Entry in Race for a /full/405258b0.html). Nature. 11 May 2000. Malaria Vaccine" (https://www.wsj.com/articles/glaxo-files-its-entry- 28. "Hall that glitters isn't shareholder gold" (http://www.telegraph.co.uk in-race-for-a-malaria-vaccine-1406218538). Wall Street Journal. /finance/2767982/Hall-that-glitters-isnt-shareholder-gold.html). . 15 July 2002. Laura Lorenzetti (24 July 2014). "GlaxoSmithKline seeks approval on 29. Reaume, Andrew (1 January 2003). "Is Corporate Venture Capital a first-ever malaria vaccine" (http://fortune.com/2014/07 Prescription for Success in the ?". The Journal /24/glaxosmithkline-seeks-approval-for-first-ever-malaria-vaccine/). of Private Equity. 6 (4): 77–87. JSTOR 43503355 Fortune. (https://www.jstor.org/stable/43503355). 30. "Press Release Peter Sears, President Of Smithkline Beecham's 8. "GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Venture Capital Fund, Appointed To AVANT Immunotherapeutics Fraud Allegations and Failure to Report Safety Data" Board Of Directors" (http://www.prnewswire.com/news-releases (http://www.justice.gov/opa/pr/2012/July/12-civ-842.html), United /peter-sears-president-of-smithkline-beechams-venture-capital-fund- States Department of Justice, 2 July 2012. appointed-to-avant-immunotherapeutics-board-of-directors- 74438092.html). AVANT, via PR Newswire. May 6, 1999. Katie Thomas and Michael S. Schmidt, "Glaxo Agrees to Pay $3 31. Salemi, Tom (3 July 2007). "Dalton Joins Pfizer" Billion in Fraud Settlement" (https://www.nytimes.com/2012/07 (http://invivoblog.blogspot.com/2007/07/dalton-joins-pfizer.html). The /03/business/glaxosmithkline-agrees-to-pay-3-billion-in-fraud- IN VIVO Blog. settlement.html), The New York Times, 2 July 2012. 32. "Press Release: S.R. One Announces New Team, Expands Fund; Simon Neville, "GlaxoSmithKline fined $3bn after bribing doctors to Premier Evergreen Fund Made 7 New Investments in 2003 | Business Wire" (http://www.businesswire.com/news/home/20040226005295 increase drugs sales" (https://www.theguardian.com/business/2012/jul /en/S.R.-Announces-Team-Expands-Fund-Premier-Evergreen). S.R. /03/glaxosmithkline-fined-bribing-doctors-pharmaceuticals), The One via Businesswire. February 26, 2004. Guardian, 3 July 2012. 33. Licking, Ellen (5 April 2011). "SR One Posts Help Wanted Ad, Again" (http://invivoblog.blogspot.com/2011/04/sr-one-posts-help- 9. R. P. T. Davenport-Hines, Judy Slinn, Glaxo: A History to 1962, wanted-ad-again.html). The IN VIVO Blog. Cambridge University Press, 1992, pp. 7–13. 34. Licking, Ellen (18 March 2010). "SR One's Revolving Door" 10. David Newton, Trademarked: A History of Well-Known Brands, from (http://invivoblog.blogspot.com/2010/03/sr-ones-revolving-door.html). Airtex to Wright's Coal Tar, The History Press, 2012, p. 435. The IN VIVO Blog. 11. David J. Ravenscraft, William F. Long, "Paths to Creating Value in 35. Huang, Gregory T. (4 April 2011). "Christoph Westphal Leaving Pharmaceutical Mergers," (http://www.nber.org/chapters/c8653.pdf) in GSK's SR One to Focus on Longwood Founders Fund" Steven N. Kaplan (ed.), Mergers and Productivity, University of (http://www.xconomy.com/boston/2011/04/04/christoph-westphal- Press, 2000. leaving-gsks-sr-one-to-focus-on-longwood-founders-fund/). Xconomy. 12. "GSK History" (https://web.archive.org/web/20110608203248/http: 36. "Press Release: Jens Eckstein named President of SR One, GSK's //www.gsk.com/about/history-noflash.htm). GlaxoSmithKline. venture healthcare group" (http://www.fiercebiotech.com/biotech/jens- Archived from the original (http://www.gsk.com/about/history- eckstein-named-president-of-sr-one-gsk-s-venture-healthcare-group). noflash.htm) on 8 June 2011. Retrieved 18 April 2011. SR One via FierceBiotech. September 9, 2011. 13. 1664-1964 "The Story of a Town" (http://eastchester350.org/350/wp- 37. "Most-recognized brands: Anti-infectives, December 2013" content/uploads/2014/04/History-of-the-town-1964.pdf), Tricentennial (http://www.drugs.com/news/most-recognized-brands-anti-infectives- Committee. december-2013-49719.html). Drugs.com. 14. "Addition to Factory" (http://news.hrvh.org/veridian/cgi- 38. Geddes AM, et al. (Dec 2007). "Introduction: historical perspective bin/senylrc?a=d&d=theeastchester19241119.1.2), The Eastchester and development of amoxicillin/clavulanate". Int J Antimicrob Agents. Citizen-Bulletin, 19 November 1924 30 (Suppl 2): S109–12. PMID 17900874 15. Peter Pennoyer, Anne Walker, The Architecture of Delano & Aldrich, (https://www.ncbi.nlm.nih.gov/pubmed/17900874). W. W. Norton & Company, 2003, p. 188 (https://books.google.com doi:10.1016/j.ijantimicag.2007.07.015 (https://doi.org /books?id=PfsvwzwaQqUC&pg=PA188). /10.1016%2Fj.ijantimicag.2007.07.015). 16. "Iconic Burroughs Wellcome Headquarters Open for Rare Public 39. Brown AG (Aug 1986). ", a novel beta-lactamase Tour" (http://recentpast.org/iconic-burroughs-wellcome-headquarters- inhibitor--a case study in and development". Drug Des open-for-rare-public-tour/), Triangle Modernist Houses, press release, Deliv. 1 (1): 1–21. PMID 3334541 (https://www.ncbi.nlm.nih.gov 8 October 2012. /pubmed/3334541). 17. Katherine Bouton, "The Nobel Pair" (https://www.nytimes.com 40. "Search" (http://www.accessdata.fda.gov/Scripts/cder/drugsatfda /1989/01/29/magazine/the-nobel-pair.html?pagewanted=all), The New /index.cfm?fuseaction=Search.DrugDetails). Food and Drug York Times, 29 January 1989. Administration. 18. Mark S. Lesney, "The ghosts of pharma past" (http://pubs.acs.org 41. D. M. Richards; R. N. Brogden (February 1985). "Ceftazidime. A /subscribe/journals/mdd/v07/i01/pdf/104timeline.pdf), Modern Drug review of its antibacterial activity, pharmacokinetic properties and Discovery, January 2004, pp. 25–26. therapeutic use". Drugs. 29 (2): 105–61. PMID 3884319 19. "10,000 face Glaxo's axe at Wellcome" (http://www.independent.co.uk (https://www.ncbi.nlm.nih.gov/pubmed/3884319). /news/business/10000-face-glaxos-axe-at-wellcome-1586547.html). doi:10.2165/00003495-198529020-00002 (https://doi.org The Independent. 15 June 1995. /10.2165%2F00003495-198529020-00002). 20. Magnus Grimond (21 June 1995). "Glaxo warns of redundancies" 42. "6-Mercaptopurine" (http://pubs.acs.org/cen/coverstory/83/8325 (http://www.independent.co.uk/news/business/glaxo-warns-of- /83256-mercaptopurine.html). Chemical & Engineering News. redundancies-1587568.html). The Independent. 43. "George Hitchings and Gertrude Elion" 21. Magnus Grimond (7 September 1995). "Glaxo Wellcome plans to axe (https://www.chemheritage.org/historical-profile/george-hitchings- 7,500 jobs" (http://www.independent.co.uk/news/business/glaxo- and-gertrude-elion). Chemical Heritage Foundation. wellcome-plans-to-axe-7500-jobs-1600042.html). The Independent. 44. Elion GB (1989). "The purine path to chemotherapy". Science. 244 22. "Glaxo to Acquire Affymax" (https://www.nytimes.com/1995/01

10 di 14 02/07/17, 14:32 GlaxoSmithKline - Wikipedia https://en.wikipedia.org/wiki/GlaxoSmithKline

(4900): 41–7. PMID 2649979 (https://www.ncbi.nlm.nih.gov/pubmed /24/idUSL2452000720070524). . /2649979). doi:10.1126/science.2649979 (https://doi.org /10.1126%2Fscience.2649979). David Cyranoski (29 October 2008). "Pharmaceutical futures: Made in 45. Lawrence K. Altman (23 February 1999). "Gertrude Elion, Drug China?" (http://www.nature.com/news/2008/081029 Developer, Dies at 81" (https://www.nytimes.com/1999/02/23/us /full/4551168a.html). Nature. /gertrude-elion-drug-developer-dies-at-81.html). The New York Times. 46. "WHO Model List of Essential Medicines. 18th list" 66. "Corporate Executive Team" (http://www.gsk.com/about-us/corporate- (http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf) executive-team.html), GlaxoSmithKline. Retrieved 16 November (PDF). World Health Organization. October 2013. 2013. Archived (https://web.archive.org/web/20121014041607/http: 47. "Glaxo Files Its Entry in Race for a Malaria Vaccine" //www.gsk.com/about-us/corporate-executive-team.html) 14 October (https://www.wsj.com/articles/glaxo-files-its-entry-in-race-for- 2012 at the Wayback Machine. a-malaria-vaccine-1406218538). Wall Street Journal. 67. "Andrew Witty's journey from Graduate to GSK CEO" 48. "Press release: Malaria vaccine candidate reduces disease over 18 (https://www.youtube.com/watch?v=FHkj9dJ6aNE), months of follow-up in late-stage study of more than 15,000 infants GlaxoSmithKline, 12 August 2008; "Andrew Philip Witty" and young children" (http://www.path.org/news/press-room/651/). (https://www.bloomberg.com/research/stocks/people PATH. /person.asp?personId=3027345&ticker=GSK), Bloomberg. 49. Birkett, A. J.; et al. (April 2013). "Malaria vaccine R&D in the Decade 68. Graham Ruddick (20 April 2009). "GlaxoSmithKline buys Stiefel for of Vaccines: breakthroughs, challenges and opportunities". Vaccine. 31 $3.6bn" (http://www.telegraph.co.uk/finance/newsbysector/epic/gsk (Supplement 2): B233–43. PMID 23598488 /5186751/GlaxoSmithKline-buys-Stiefel-for-3.6bn.html). The Daily (https://www.ncbi.nlm.nih.gov/pubmed/23598488). Telegraph. doi:10.1016/j.vaccine.2013.02.040 (https://doi.org 69. "FDA Approves Additional Vaccine for 2009 H1N1 Influenza Virus" /10.1016%2Fj.vaccine.2013.02.040). (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements 50. "Malaria vaccine candidate reduces disease over 18 months of follow- /ucm190783.htm). US Food and Drug Administration (FDA). 16 up in late-stage study of more than 15,000 infants and young children, November 2009. Malaria vaccine candidate reduces disease over 18 months of follow- 70. Andrew Jack (16 April 2009). "Companies / Pharmaceuticals – GSK up in late-stage study of more than 15,000 infants and young children | and Pfizer to merge HIV portfolios" (http://www.ft.com/cms/s 2013 | Press releases | Media | GlaxoSmithKline" /0/5327ff12-2aaa-11de-8415-00144feabdc0.html). . (https://web.archive.org/web/20140407081405/http://www.gsk.com 71. GSK Acquires Laboratorios Phoenix for $253m /media/press-releases/2013/malaria-vaccine-candidate-reduces- (http://www.infogrok.com/index.php/pharma-companies/gsk-acquires- disease-over-18-months-of-foll.html). Archived from the original laboratorios-phoenix.html), InfoGrok. (http://www.gsk.com/media/press-releases/2013/malaria-vaccine- 72. Paul Sandle (13 December 2010). "UPDATE 2-Glaxo buys protein- candidate-reduces-disease-over-18-months-of-foll.html) on 7 April drinks firm Maxinutrition" (https://www.reuters.com/article 2014. /idUSLDE6BC0XO20101213). Reuters. 51. Donald G. McNeil Jr (18 October 2011). "Glaxo's RTS, S Malaria 73. David Ranii (21 December 2011). "GSK sells BC, Goody's and other Vaccine Shows Promise, Scientists Say" (https://www.nytimes.com brands" (https://web.archive.org/web/20120415192244/http: /2011/10/19/health/19malaria.html). The New York Times. //blogs.newsobserver.com:80/business/gsk-sells-bc-goodys-and-other- 52. "Product pipeline | GSK" (http://www.gsk.com/en-gb/research/what- brands). News & Observer. Archived from the original we-are-working-on/product-pipeline/). (http://blogs.newsobserver.com/business/gsk-sells-bc-goodys-and- 53. Angela Monaghan "Ribena and Lucozade sold to Japanese drinks other-brands) on 15 April 2012. giant" (https://www.theguardian.com/business/2013/sep/09/ribena- 74. "GSK confirms 500 mln stg UK investment plans" lucozade-sold-japan-glaxosmithkline), , 9 September (https://www.reuters.com/article/2012/03/22/glaxosmithkline-britain- 2013 idUSWLA506520120322), Reuters, 22 March 2012. 54. Majumdar, Ramanuj (2007). Product management in India 75. European Biotechnology News 16 May 2012. GSK acquires Cellzome (https://books.google.co.uk/books?id=vI9vE7_LJX4C&pg=PT242&) 100%: Britain's largest drugmaker GlaxoSmithKline will pay about (3rd ed.). PHI Learning. p. 242. ISBN 978-81-203-3383-3. €75m in cash to acquire Cellzome AG completely 55. Aaron Smith, "Alli weight-loss drug recalled for tampering" (http://www.european-biotechnology-news.com/news/news/2012-02 (http://money.cnn.com/2014/03/27/news/companies/glaxosmithkline- /gsk-acquires-cellzome-100.html); John Carroll for FierceBiotech 15 alli-recall), CNN, 27 March 2014. May 2012 GSK snags proteomics platform tech in $98M Cellzome 56. "About us: what we do" (http://www.gsk.com/about-us/what-we- buyout (http://www.fiercebiotech.com/story/gsk-snags-proteomics- do.html), GlaxoSmithKline, accessed 16 November 2013 Archived platform-tech-98m-cellzome-buyout/2012-05-15) (https://web.archive.org/web/20131013192519/http://www.gsk.com 76. John Carroll for FiercePharma. 12 June 2012 GSK continues deal /about-us/what-we-do.html) 13 October 2013 at the Wayback spree with $302M pact for Basilea eczema drug Machine. (http://www.fiercebiotech.com/story/gsk-continues-deal-spree-302m- 57. "Sir Henry Dale - Biographical" (https://www.nobelprize.org deal-eczema-drug/2012-06-12); Basilea Pharmaceutica Press Release. /nobel_prizes/medicine/laureates/1936/dale-bio.html). 11 June 2012 Basilea enters into global agreement with Stiefel, a GSK 58. "John R. Vane - Biographical" (https://www.nobelprize.org company, for Toctino® (alitretinoin) (http://hugin.info/134390 /nobel_prizes/medicine/laureates/1982/vane-bio.html). /R/1618919/516985.pdf) 59. Maltzman JS, Koretzky GA (April 2003). "Azathioprine: old drug, 77. Matthew Herper, "Three Lessons From GlaxoSmithKline's Purchase new actions" (https://www.ncbi.nlm.nih.gov/pmc/articles Of Human Genome Sciences" (http://www.forbes.com/sites /PMC152947). J. Clin. Invest. 111: 1122–4. PMC 152947 /matthewherper/2012/07/16/three-lessons-from-glaxosmithklines- (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC152947) . purchase-of-human-genome-sciences/), Forbes, 16 July 2012. PMID 12697731 (https://www.ncbi.nlm.nih.gov/pubmed/12697731). 78. Hirschler, Ben (10 March 2014). "GSK pays $1 billion to lift Indian doi:10.1172/JCI18384 (https://doi.org/10.1172%2FJCI18384). unit stake to 75 percent" (https://www.reuters.com/article/2014/03 60. Elion GB (1993). "Acyclovir: discovery, mechanism of action, and /10/us-glaxosmithkline-india-idUSBREA2909U20140310). Reuters. selectivity". J. Med. Virol. Suppl 1: 2–6. PMID 8245887 Retrieved 10 March 2014. (https://www.ncbi.nlm.nih.gov/pubmed/8245887). 79. Chad Bray, David Jolly, "Novartis and Glaxo Agree to Trade $20 61. Koenig R (2006). "The legacy of great science: the work of Nobel Billion in Assets" (https://dealbook.nytimes.com/2014/04/22/novartis- Laureate Gertrude Elion lives on". Oncologist. 11 (9): 961–5. announces-major-restructuring/?_php=true&_type=blogs&_r=0), The PMID 17030634 (https://www.ncbi.nlm.nih.gov/pubmed/17030634). New York Times', 22 April 2014. doi:10.1634/theoncologist.11-9-961 (https://doi.org 80. Jonathan D. Rockoff, Jeanne Whalen, Marta Falconi, "Deal Flurry /10.1634%2Ftheoncologist.11-9-961). Shows Drug Makers' Swing Toward Specialization" 62. "GlaxoSmithKline Completes the Purchase of Block Drug for (https://www.wsj.com/news/articles $1.24 Billion" (http://www.prnewswire.com/news-releases /SB10001424052702303825604579518054271953092), The Wall /glaxosmithkline-completes-the-purchase-of-block-drug-for-124- Street Journal, 22 April 2014. billion-71032672.html). PR Newswire. Retrieved 1 August 2010. 81. "GEN - News Highlights:GSK Acquires GlycoVaxyn for $190M" 63. Rick Stouffer (9 October 2006). "Glaxo unit buys Breathe Right (http://www.genengnews.com/gen-news-highlights/gsk-acquires- maker" (http://triblive.com/x/pittsburghtrib/business/s_474181.html). glycovaxyn-for-190m/81250916/). GEN. Trib Live. 82. "Pfizer Buys Two GSK Meningitis Vaccines for $130M" 64. "Sir Christopher Gent to exit GlaxoSmithKline" (http://www.genengnews.com/gen-news-highlights/pfizer-buys-two- (http://www.telegraph.co.uk/finance/newsbysector gsk-meningitis-vaccines-for-130m/81251415/). GEN. Retrieved /pharmaceuticalsandchemicals/9639020/Sir-Christopher-Gent-to-exit- 25 March 2016. GlaxoSmithKline.html), The Daily Telegraph, 28 October 2012. 83. James Quinn, "Sir Philip Hampton to chair Glaxo" 65. Ben Hirschler (24 May 2007). "Glaxo China R&D centre to target (http://www.telegraph.co.uk/finance/newsbysector neurodegeneration" (https://www.reuters.com/article/2007/05 /pharmaceuticalsandchemicals/11120385/Sir-Philip-Hampton-to-chair- Glaxo.html), The Daily Telegraph, 25 September 2014.

11 di 14 02/07/17, 14:32 GlaxoSmithKline - Wikipedia https://en.wikipedia.org/wiki/GlaxoSmithKline

84. Jon Yeomans (20 September 2016). "Emma Walmsley becomes latest PMID 12163427 (https://www.ncbi.nlm.nih.gov/pubmed/12163427). female CEO in FTSE 100 as she replaces Sir Andrew Witty at GSK" doi:10.1161/01.CIR.0000025403.20953.23 (https://doi.org (http://www.telegraph.co.uk/business/2016/09/20/glaxosmithkline- /10.1161%2F01.CIR.0000025403.20953.23). names-emma-walmsley-to-replace-sir-andrew-witty/). Daily Telegraph, London. Retrieved 20 September 2016. 100. Nissen SE (2010). "The rise and fall of rosiglitazone". European Heart 85. "Access to medicine" (https://web.archive.org/web/20140207165041 Journal. 31 (7): 773–776. PMID 20154334 /http://www.accesstomedicineindex.org/sites (https://www.ncbi.nlm.nih.gov/pubmed/20154334). /www.accesstomedicineindex.org/files doi:10.1093/eurheartj/ehq016 (https://doi.org /longitudinal_analysis_2010-2012_access_to_medicine_index.pdf) /10.1093%2Feurheartj%2Fehq016). see table 1 for timeline. (PDF). Archived from the original 101. Philip D. Home, et al., "Rosiglitazone evaluated for cardiovascular (http://www.accesstomedicineindex.org/sites outcomes in oral agent combination therapy for type 2 diabetes /www.accesstomedicineindex.org/files (RECORD): a multicentre, randomised, open-label trial," , /longitudinal_analysis_2010-2012_access_to_medicine_index.pdf) 373(9681), 20 June 2009, pp. 2125–2135 (PDF) on 7 February 2014. doi:10.1016/S0140-6736(09)60953-3 (https://dx.doi.org 86. Human Rights Campaign. Profle: Buyers Guide entry for /10.1016%2FS0140-6736%2809%2960953-3) PMID 19501900 GlaxoSmithKline (http://www.hrc.org/apps/buyersguide (https://www.ncbi.nlm.nih.gov/pubmed/19501900) /profile.php?orgid=1563#.UUMVCzdF8zI). Accessed May 16, 2014 87. "Global alliance to eliminate Lymphatic Filariasis" Philip D. Home, et al., "Rosiglitazone Evaluated for Cardiac (https://web.archive.org/web/20081227072400/http://www.ifpma.org Outcomes and Regulation of Glycaemia in Diabetes (RECORD): /index.php?id=588). Ifpma.org. Archived from the original study design and protocol," Diabetologia, 48(9), September 2005, pp. (http://www.ifpma.org/index.php?id=588) on 27 December 2008. 1726–1735. doi:10.1007/s00125-005-1869-1 (https://dx.doi.org 88. "Private and Public Partners Unite to Combat 10 Neglected Tropical /10.1007%2Fs00125-005-1869-1) PMID 16025252 Diseases by 2020" (http://www.gatesfoundation.org/media-center (https://www.ncbi.nlm.nih.gov/pubmed/16025252) /press-releases/2012/01/private-and-public-partners-unite-to-combat- "RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and 10-neglected-tropical-diseases-by-2020). Bill & Melinda Gates Foundation. 30 January 2012. Regulation of Glycaemia in Diabetes" (https://clinicaltrials.gov /show/NCT00379769), clinicaltrials.gov. "Research-based pharma pledges on neglected tropical diseases" (http://www.thepharmaletter.com/file/110665/research-based-pharma- 102. Nissen SE, Wolski K (2007). "Effect of Rosiglitazone on the Risk of and Death from Cardiovascular Causes". New pledges-on-neglected-tropical-diseases.html). The Pharma Letter. 31 England Journal of Medicine. 356 (24): 2457–2471. PMID 17517853 January 2012. (https://www.ncbi.nlm.nih.gov/pubmed/17517853). doi:10.1056/NEJMoa072761 (https://doi.org 89. "Global programme to eliminate lymphatic filariasis: progress report, /10.1056%2FNEJMoa072761). "Rosiglitazone was associated with a 2014" (http://www.who.int/wer/2015/wer9038.pdf) (PDF). World significant increase in the risk of myocardial infarction and with an Health Organization. 18 September 2015. p. 490. increase in the risk of death from cardiovascular causes that had 90. Sarah Boseley, "Drug giant GlaxoSmithKline pledges cheap medicine borderline significance." for world's poor" (https://www.theguardian.com/business/2009/feb 103. Stephanie Saul, "Doctor Accused of Leak to Drug Maker" /13/glaxo-smith-kline-cheap-medicine), The Guardian, 13 February (https://www.nytimes.com/2008/01/30/business/30cnd-censure.html), 2009. The New York Times, 30 January 2008. 91. UNITAID 16 February 2009. UNITAID Statement on GSK Patent Pool For Neglected Diseases (http://www.unitaid.eu/en/resources Gardiner Harris, "A Face-Off on the Safety of a Drug for Diabetes" /press-centre/news/158-unitaid-statement-on-gsk-patent-pool-for- (https://www.nytimes.com/2010/02/23/health/23niss.html), The New neglected-diseases) 92. Tido von Schoen-Angerer, Letter to the editor York Times, 22 February 2010. (http://www.msfaccess.org/content/guardian-letter-response-gsks- patent-pool-proposal), The Guardian, 16 February 2009.] 104. "Staff report on GlaxoSmithKline and the diabetes drug Avandia" 93. "GlaxoSmithKline unit joins patent pool for AIDS drugs | Reuters" (http://www.finance.senate.gov/newsroom/chairman/download (https://www.reuters.com/article/2013/02/27/us-aids-drugs-patents- /?id=9e4b091f-de21-4df1-b65e-b227d74bec12), Committee on idUSBRE91Q0P520130227). Finance, United States Senate, January 2010. 94. "Medicines Patent Pool, ViiV Healthcare Sign Licence for the Most "Grassley, Baucus Release Committee Report on Avandia" Recent HIV Medicine to Have Received Regulatory Approval | (http://www.finance.senate.gov/newsroom/chairman/release Medicines Patent Pool" (http://www.medicinespatentpool.org /?id=bc56b552-efc5-4706-968d-f7032d5cd2e4), The United States /medicines-patent-pool-viiv-healthcare-sign-licence-for-the-most- Senate Committee on Finance, 20 February 2010. recent-hiv-medicine-to-have-received-regulatory-approval/). 95. , , Fourth Estate, 2013 [2012], p. 387. Andrew Clark, "Glaxo's handling of Avandia concerns damned by US 96. , , "Finance Committee Letter to the FDA Senate committee" (https://www.theguardian.com/business/2010/feb Regarding Avandia" (http://finance.senate.gov/newsroom/chairman /22/glaxosmithkline-avandia-concerns-senate), The Guardian, 22 /download/?id=a5c07780-6351-4905-8c63-52e4a7a7a66b), United February 2010. States Senate Finance Committee, 12 July 2010. 105. David Graham, "Assessment of the cardiovascular risks and health Jim Edwards, "Inside GSK's CASSPER Ghostwriting Program" benefits of rosiglitazone" (http://www.fda.gov/ohrms/dockets/ac/07 (http://www.cbsnews.com/news/inside-gsks-cassper-ghostwriting- /slides/2007-4308s1-08-fda-graham_files/frame.htm), Office of program/), CBS News, 21 August 2009. Surveillance and Epidemiology, Food and Drug Administration, 30 July 2007. 97. "GSK to stop paying doctors in major marketing overhaul" 106. "FDA Adds Boxed Warning for Heart-related Risks to Anti-Diabetes (http://sustainability.thomsonreuters.com/2013/12/17/gsk-stop-paying- Drug Avandia. Agency says drug to remain on market, while safety doctors-major-marketing-overhaul), Thomson/Reuters, 17 December assessment continues" (http://www.fda.gov/NewsEvents/Newsroom 2013. /PressAnnouncements/2007/ucm109026.htm), Food and Drug 98. "The Intimidation of Dr. John Buse and the Diabetes Drug Avandia" Administration, 14 November 2007. (http://www.finance.senate.gov/download/?id=883E903D- 107. "FDA Drug Safety Communication: FDA requires removal of some F973-4A74-8432-3C651C71B4B4), Committee on Finance, United prescribing and dispensing restrictions for rosiglitazone-containing States Senate, November 2007, pp. 2–4. diabetes medicines" (http://www.fda.gov/Drugs/DrugSafety 99. Max Baucus, Chuck Grassley, "Finance Committee Letter to the FDA /ucm376389.htm). Food and Drug Administration. 25 November Regarding Avandia" (http://finance.senate.gov/newsroom/chairman 2013. /download/?id=a5c07780-6351-4905-8c63-52e4a7a7a66b), United States Senate Finance Committee, 12 July 2010; for internal concerns, Avandia. Prescribing information" (http://www.fda.gov/downloads p. 2 and attachment E, pp. 20–35; for ghostwriting, p. 3 and /Drugs/DrugSafety attachment H, pp. 58–109; for the ghostwriting, attachment I, p. 110ff; /PostmarketDrugSafetyInformationforPatientsandProviders for cover letter to Circulation, attachment I, p. 143; for the /UCM143413.pdf), Food and Drug Administration. ghostwritten article, attachment I, pp. 152–158. 108. Thomas F. Lüscher; Ulf Landmesser; Frank Ruschitzka (23 April Haffner SM, et al. (2002). " ", 2002 "Effect of Rosiglitazone Treatment 2010). "Standing firm—the European Heart Journal, scientific on Nontraditional Markers of Cardiovascular Disease in Patients With controversies and the industry". European Heart Journal. 31 (10): Type 2 Diabetes Mellitus". Circulation. 106 (6): 679–684. 1157–1158. doi:10.1093/eurheartj/ehq127 (https://doi.org

12 di 14 02/07/17, 14:32 GlaxoSmithKline - Wikipedia https://en.wikipedia.org/wiki/GlaxoSmithKline

/10.1093%2Feurheartj%2Fehq127). Jon N. Jureidini, Leemon B. McHenry, Peter R. Mansfield, "Clinical Steven E. Nissen, "The rise and fall of rosiglitazone," European Heart trials and drug promotion: Selective reporting of study 329", Journal, 31(7), April 2010, pp. 773–776. doi:10.1093/eurheartj International Journal of Risk & Safety in Medicine, 20, 2008, pp. 73–81. doi:10.3233/JRS-2008-0426 (https://dx.doi.org /ehq016 (https://dx.doi.org/10.1093%2Feurheartj%2Fehq016) /10.3233%2FJRS-2008-0426) PMID 20154334 (https://www.ncbi.nlm.nih.gov/pubmed/20154334) , "The rise and fall of rosiglitazone: reply," European "Company hid suicide link" (http://news.bbc.co.uk/2/hi/health Heart Journal, 31(7), April 2010, pp. 1282–1284. /6308871.stm), BBC News, 29 January 2007; "Secrets of the Drug doi:10.1093/eurheartj/ehq118 (https://dx.doi.org Trials," BBC Panorama, 29 January 2007; Goldacre 2013, pp. /10.1093%2Feurheartj%2Fehq118) PMID 20499440 296–297. (https://www.ncbi.nlm.nih.gov/pubmed/20499440) 117. Martin Keller, et al., "Efficacy of paroxetine in the treatment of Michel Komajda, et al, "Heart failure events with rosiglitazone in type adolescent major depression: a randomized, controlled trial" 2 diabetes: data from the RECORD clinical trial," European Heart (http://www.justice.gov/sites/default/files/opa/legacy/2012/07 Journal, 31(7), April 2010, pp. 824–831. doi:10.1093/eurheartj /02/complaint-ex2.pdf), Journal of the American Academy of Child /ehp604 (https://dx.doi.org/10.1093%2Feurheartj%2Fehp604) and Adolescent Psychiatry, 40(7), July 2001, pp. 762–772. PMID 20118174 (https://www.ncbi.nlm.nih.gov/pubmed/20118174) PMID 11437014 (https://www.ncbi.nlm.nih.gov/pubmed/11437014) doi:10.1097/00004583-200107000-00010 (https://dx.doi.org 109. Steven E. Nissen, Kathy Wolski, "Rosiglitazone RevisitedAn Updated /10.1097%2F00004583-200107000-00010) Meta-analysis of Risk for Myocardial Infarction and Cardiovascular 118. Alison Bass, Side Effects: A Prosecutor, a Whistleblower, and a Mortality," Archives of Internal Medicine, 170(14), July 2010, pp. Bestselling on Trial, Algonquin Books of Chapel Hill, 1191–1202: "That study was limited by low event rates, which 2008. resulted in insufficient statistical power to confirm or refute evidence of an increased risk for ischemic myocardial events." (15 January 2009). "Drug Companies & Doctors: A doi:10.1001/archinternmed.2010.207 (https://dx.doi.org Story of " (http://www.nybooks.com/articles/archives /10.1001%2Farchinternmed.2010.207) PMID 20656674 /2009/jan/15/drug-companies-doctorsa-story-of-corruption/). The New (https://www.ncbi.nlm.nih.gov/pubmed/20656674) York Review of Books. 56 (1). 110. "European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim" (http://www.ema.europa.eu 119. "Judge: Paxil ads can't say it isn't habit-forming" /ema/index.jsp?curl=pages/news_and_events/news/2010 (http://www.usatoday.com/news/health/2002-08-20-paxil-ads_x.htm). /09/news_detail_001119.jsp&murl=menus/news_and_events Associated Press. 20 August 2002. /news_and_events.jsp&mid=WC0b01ac058004d5c1& 120. Drug and Device Law. December 14, 2006 The FDA's Amicus Briefs jsenabled=false), European Medicines Agency, 23 September 2010. on Preemption (http://druganddevicelaw.blogspot.com/2006/12/fdas- 111. Kenneth W. McHaffey, et al., "Results of a reevaluation of amicus-briefs-on-preemption.html) cardiovascular outcomes in the RECORD trial," American Heart Journal, 166(2), August 2013, pp. 240–249. Ronald D. White for the Los Angeles Times. August 21, 2002 U.S. doi:10.1016/j.ahj.2013.05.004 (https://dx.doi.org Opposes Order to Pull Paxil TV Ads (http://articles.latimes.com /10.1016%2Fj.ahj.2013.05.004) PMID 23895806 /2002/aug/21/business/fi-paxil21) (https://www.ncbi.nlm.nih.gov/pubmed/23895806) 112. "FDA requires removal of certain restrictions on the diabetes drug 121. "WHO Expert Committee on Drug Dependence" Avandia" (http://www.fda.gov/NewsEvents/Newsroom (https://web.archive.org/web/20150418195400/http://apps.who.int /PressAnnouncements/ucm376516.htm), Food and Drug /medicinedocs/collect/medicinedocs/pdf/s4896e/s4896e.pdf), Thirty- Administration, 25 November 2013. third Report, World Health Organization, 2003, pp. 20, 25. "Readjudication of the Rosiglitazone Evaluated for Cardiovascular 122. United States v. Glaxo Group Ltd. (http://caselaw.findlaw.com/us- Outcomes and Regulation of Glycemia in Diabetes Trial (RECORD)" supreme-court/410/52.html), 410 U.S. 52 (1973). (http://www.fda.gov/downloads/AdvisoryCommittees 123. LaHatte, Gabrielle (2011). "Reverse Payments: When the Federal /CommitteesMeetingMaterials/Drugs Trade Commission can Attack the Validity of Underlying Patents" /EndocrinologicandMetabolicDrugsAdvisoryCommittee (http://scholarlycommons.law.case.edu /UCM354859.pdf), Joint Meeting of the Endocrinologic and /cgi/viewcontent.cgi?article=1051&context=jolti). Case Western Metabolic Drugs Advisory Committee and the Drug Safety and Risk Reserve Journal of Law, Technology & the Internet. 2: 37–73. Management Advisory Committee, Food and Drug Administration, Retrieved 19 June 2015. 5–6 June 2013. 124. Leslie, Christopher R. (2011). Antitrust Law and Intellectual Property Rights: Cases and Materials. Oxford University Press. pp. 574–75. Steven Nissen, "Steven Nissen: The Hidden Agenda Behind The ISBN 9780195337198. FDA's New Avandia Hearings" (http://www.forbes.com/sites 125. United States v. Glaxo Group Ltd. (http://caselaw.findlaw.com/us- /matthewherper/2013/05/23/steven-nissen-the-hidden-agenda-behind- supreme-court/410/52.html) at 62-63. the-fdas-avandia-hearings/), Forbes, 23 May 2013. 126. Jacobson, Jonathan M. (2007). Antitrust Law Developments. American Bar Association. p. 1162. ISBN 9781590318676. "The FDA Responds To Steve Nissen's Criticism Of Upcoming 127. Oliver Thring, "Consider squash and cordial" Avandia Meeting" (http://www.forbes.com/sites/matthewherper (https://www.theguardian.com/lifeandstyle/wordofmouth/2010/sep /2013/05/23/the-fda-responds-to-steve-nissens-criticism-of-upcoming- /07/consider-squash-cordial), The Guardian, 7 September 2010. avandia-meeting/), Forbes, 23 May 2013. "We have Frank and Vernon to thank for Ribena" 113. W. Kondro; B. Sibbald (March 2004). "Drug company experts advised (http://www.bristolpost.co.uk/Frank-Vernon-thank-Ribena/story- staff to withhold data about SSRI use in children" (http://www.cmaj.ca 19804329-detail/story.html), The Bristol Post, 17 September 2013. /content/170/5/783.long). Canadian Medical Association Journal. 170 (5): 783. PMC 343848 (https://www.ncbi.nlm.nih.gov/pmc/articles 128. Linus Gregoriadis, "Makers of Ribena lose fight over anti-decay /PMC343848) . PMID 14993169 (https://www.ncbi.nlm.nih.gov claims" (http://www.telegraph.co.uk/news/uknews/1318417/Makers- /pubmed/14993169). doi:10.1503/cmaj.1040213 (https://doi.org of-Ribena-lose-fight-over-anti-decay-claims.html), The Daily /10.1503%2Fcmaj.1040213). Telegraph, 18 January 2001. 114. Goldacre 2013, p. 58. 129. David Eames (28 March 2007). "Judge orders Ribena to fess up" 115. Kurt Samson (December 2008). "Senate probe seeks industry payment (http://www.nzherald.co.nz/section/1/story.cfm?c_id=1& data on individual academic researchers". Annals of Neurology. 64 (6): objectid=10431253). The New Zealand Herald. A7–9. PMID 19107985 (https://www.ncbi.nlm.nih.gov/pubmed /19107985). doi:10.1002/ana.21271 (https://doi.org Tony Jaques, "When an Icon Stumbles – The Ribena Issue /10.1002%2Fana.21271). Mismanaged" (http://issueoutcomes.publishpath.com/Websites 116. Letter showing authorship of Study 239 (http://dida.library.ucsf.edu /issueoutcomes/Images/Ribena%20icon%20stumbles%20CCIJ.pdf), /pdf/otu38h10), Drug Industry Document Archive, University of Corporate Communications: An International Journal, 13(4), 2008, California, San Francisco. pp. 394–406. Isabel Heck, "Controversial Paxil paper still under fire 13 years later" Michael Regester, Judy Larkin, Risk Issues and Crisis Management in (http://www.browndailyherald.com/2014/04/02/controversial-paxil- Public Relations, Kogan Page Publishers, 2008, p. 67ff paper-still-fire-13-years-later/), The Brown Daily Herald, 2 April (https://books.google.com/books?id=MIIx4NVTz6EC&pg=PA67). 2014. 130. "GlaxoSmithKline to Plead Guilty & Pay $750 Million to Resolve

13 di 14 02/07/17, 14:32 GlaxoSmithKline - Wikipedia https://en.wikipedia.org/wiki/GlaxoSmithKline

Criminal and Civil Liability Regarding Manufacturing Deficiencies at /newsbysector/pharmaceuticalsandchemicals/11108376/China-fines- Puerto Rico Plant" (http://www.justice.gov/opa/pr/2010/October/10- Glaxo-297m-for-bribery-Mark-Reilly-sentenced.html), The Daily civ-1205.html), U.S. Department of Justice, 26 October 2010. Telegraph, 19 September 2014. 131. "Glaxo to Pay $750 Million for Sale of Bad Products" 136. "Watchdog fines GSK £37m for paying to keep generic drugs out of (https://www.nytimes.com/2010/10/27/business/27drug.html). The UK market" (http://www.telegraph.co.uk/finance/newsbysector New York Times. 27 October 2010. /pharmaceuticalsandchemicals/12153450/Watchdog-fines-GSK-37m- 132. Alice Yan; Toh Han Shih (16 July 2013). "Shanghai travel agent's for-paying-to-keep-generic-drugs-out-of-UK-market.html). Daily revenue surge led to arrests in GSK bribery case" Telegraph. 12 February 2016. Retrieved 12 February 2016. (http://www.scmp.com/news/china/article/1283207/glaxosmithkline- 137. John Hooper, Heather Stewart, "Over 4,000 doctors face charges in suspects-drug-bribery-probe-identified). South China Morning Post. Italian drugs scandal" (https://www.theguardian.com/world/2004/may /27/italy.heatherstewart), The Guardian, 27 May 2004. "GlaxoSmithKline executives face China bribery probe" 138. Jane Burgermeister, "German prosecutors probe again into bribes by (http://www.bbc.co.uk/news/business-23265958). BBC News. 11 July drug companies" (http://www.ncbi.nlm.nih.gov/pmc/articles 2013. /PMC420312/pdf/bmj3281333a.pdf), BMJ, 328, 5 June 2004; "Glaxo probed over doctor freebies" (http://news.bbc.co.uk/2/hi/business 133. Rupert Neate and Angela Monaghan, "GlaxoSmithKline admits some /1869162.stm), BBC News, 12 March 2002. staff in China involved in bribery" (https://www.theguardian.com 139. "GlaxoSmithKline Annual Report pg 177" (https://www.gsk.com /business/2013/jul/22/glaxosmithkline-admits-bribery-china), The /media/2684/annual-report-2008.pdf) (PDF). Retrieved 2015-10-08. Guardian, 22 July 2013. 140. "GlaxoSmithKline to Settle Tax Dispute With U.S." (https://www.nytimes.com/2006/09/12/business/worldbusiness Rupert Neate, "GSK’s China crisis: chief executive Andrew Witty /12glaxo.html), Reuters, 12 September 2006; "IRS Accepts Settlement speaks - as it happened" (https://www.theguardian.com/business Offer in Largest Transfer Pricing Dispute" (http://www.irs.gov /2013/jul/24/gsk-china-crisis-ceo-andrew-witty-live), The Guardian, /uac/IRS-Accepts-Settlement-Offer-in-Largest-Transfer-Pricing- 24 July 2013. Dispute), IRS, 11 September 2006. Tom Philips (26 July 2013). "Chinese police allege Glaxo sales reps 141. Julia Kollewe (28 May 2014). "GlaxoSmithKline faces criminal investigation by Serious Fraud Office" (https://www.theguardian.com trained to offer sexual bribes" (http://www.telegraph.co.uk/finance /business/2014/may/28/serious-fraud-office-investigates- /newsbysector/pharmaceuticalsandchemicals/10204304/Chinese- glaxosmithkline). The Guardian. police-allege-Glaxo-sales-reps-trained-to-offer-sexual-bribes.html). 142. Kirsten Ridley, "UK fraud office liaising with China on GSK bribery The Daily Telegraph. case" (https://www.reuters.com/article/2014/07/23/us-britain-fraud- sfo-gsk-idUSKBN0FS1U320140723), Reuters, 23 July 2014. 134. "China Fines GlaxoSmithKline Nearly $500 Million in Bribery Case - 143. "GlaxoSmithKline faces bribery claims in Syria" The New York Times" (https://www.nytimes.com/2014/09/20/business (http://www.telegraph.co.uk/finance/newsbysector /international/gsk-china-fines.html). /pharmaceuticalsandchemicals/11027538/Serious-Fraud-Office-opens- 135. Malcolm Moore, Denise Roland, "China fines Glaxo £297m for criminal-investigation-into-GlaxoSmithKline.html), Reuters, 12 bribery, Mark Reilly sentenced" (http://www.telegraph.co.uk/finance August 2014. External links

Official website (http://www.gsk.com/) GlaxoSmithKline companies (https://opencorporates.com/corporate_groupings/GlaxoSmithKline) grouped at OpenCorporates Financial Times Quote, profile, and news (http://briefings.ft.com/company/news.html?extelID=00044814&query=UK:GSK®ion=& industry=) London Stock Exchange Quote, regulatory filings, and news (https://web.archive.org/web/20070617040743/http: //www.londonstockexchange.com/en-gb/pricesnews/prices/system /detailedprices.htm?sym=GB0009252882GBGBXSET10925288GSK) Quote, profile, regulatory filings, and news (http://www.nyse.com/about/listed/lcddata.html?ticker=GSK)

Retrieved from "https://en.wikipedia.org/w/index.php?title=GlaxoSmithKline&oldid=788610932"

Categories: Biotechnology companies of the Companies based in the London Borough of Hounslow Companies listed on the New York Stock Exchange Dental companies GlaxoSmithKline Medical controversies Multinational companies headquartered in England Pharmaceutical companies established in 2000 British companies established in 2000 Pharmaceutical companies of the United Kingdom Vaccine producers Orphan drug companies Life sciences industry 2000 establishments in the United Kingdom Biotechnology companies established in 2000 Companies formed by merger

This page was last edited on 2 July 2017, at 11:56. Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.

14 di 14 02/07/17, 14:32